lorazepam has been researched along with Alzheimer Disease in 9 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with Alzheimer's disease and ten age-matched normal controls were studied in a double-blind, placebo-controlled acute trial of 1 mg PO lorazepam to test the effects of low-dose benzodiazepine on memory and behavior in a mostly older population." | 2.66 | Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. ( Cohen, RM; Lawlor, BA; Mueller, EA; Newhouse, PA; Sunderland, T; Tariot, PN; Thompson, KE; Weingartner, H, 1989) |
| "Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed." | 2.41 | Guidelines for managing Alzheimer's disease: Part II. Treatment. ( Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B, 2002) |
| "Drug-induced delirium is a common matter in the elderly and anticholinergics, together with a number of different drugs, may significantly contribute to the delirium onset, especially in demented people." | 1.34 | Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient. ( Cotroneo, A; De Fazio, P; De Fazio, S; De Sarro, G; Gallelli, L; Gareri, P; Lacava, R, 2007) |
| "A 75-years-old man with Alzheimer's disease, treated with the cholinesterase inhibitor donepezil for 14 months, was scheduled for left colectomy under general anesthesia." | 1.32 | [Interaction of donepezil and muscular blockers in Alzheimer's disease]. ( Demartini Ferrari, A; Roca de Togores López, A; Sánchez Morillo, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stonnington, CM | 1 |
| Snyder, PJ | 1 |
| Hentz, JG | 1 |
| Reiman, EM | 1 |
| Caselli, RJ | 1 |
| Sánchez Morillo, J | 1 |
| Demartini Ferrari, A | 1 |
| Roca de Togores López, A | 1 |
| Lange, N | 1 |
| Gareri, P | 1 |
| De Fazio, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Reid, C | 1 |
| Hatch, CD | 1 |
| Lund, BC | 1 |
| Perry, PJ | 1 |
| Cummings, JL | 1 |
| Frank, JC | 1 |
| Cherry, D | 1 |
| Kohatsu, ND | 1 |
| Kemp, B | 1 |
| Hewett, L | 1 |
| Mittman, B | 1 |
| Sunderland, T | 2 |
| Weingartner, H | 2 |
| Cohen, RM | 2 |
| Tariot, PN | 2 |
| Newhouse, PA | 2 |
| Thompson, KE | 1 |
| Lawlor, BA | 1 |
| Mueller, EA | 1 |
| Thompson, K | 1 |
| Mellow, AM | 1 |
| Murphy, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Lorazepam on Cognition in APOE e4 Carriers[NCT00586430] | 36 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode[NCT04211961] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for lorazepam and Alzheimer Disease
| Article | Year |
|---|---|
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; D | 2002 |
3 trials available for lorazepam and Alzheimer Disease
| Article | Year |
|---|---|
What can modern statistics offer imaging neuroscience?
Topics: Alzheimer Disease; Brain Mapping; GABA Modulators; Hippocampus; Humans; Lorazepam; Magnetic Resonanc | 2003 |
Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls.
Topics: Administration, Oral; Alzheimer Disease; Attention; Dose-Response Relationship, Drug; Female; Humans | 1989 |
The effects of acute scopolamine in geriatric depression.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Cognition; Depressive Disorder; Diagnosis, Differ | 1988 |
5 other studies available for lorazepam and Alzheimer Disease
| Article | Year |
|---|---|
Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Cognition; Cognition Disorders; Cross-Over Stud | 2009 |
[Interaction of donepezil and muscular blockers in Alzheimer's disease].
Topics: Acetylcholine; Aged; Alzheimer Disease; Anesthesia, General; Atracurium; Cholinesterase Inhibitors; | 2003 |
Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.
Topics: Acute Disease; Aged, 80 and over; Alzheimer Disease; Amitriptyline; Antipsychotic Agents; Cholinergi | 2007 |
Medicating "Margaret".
Topics: Advance Directives; Alzheimer Disease; Analgesics, Opioid; Antipsychotic Agents; Electroconvulsive T | 2006 |
Failed challenge with quetiapine after neuroleptic malignant syndrome with conventional antipsychotics.
Topics: Alzheimer Disease; Antipsychotic Agents; Chlorpromazine; Dibenzothiazepines; Haloperidol; Humans; Hy | 2001 |